Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
2.436
USD
|
+0.27%
|
|
-1.75%
|
-60.38%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
277.5
|
99.86
|
34.22
|
8.491
|
43.01
|
17.04
|
-
|
-
|
Enterprise Value (EV)
1 |
277.5
|
99.86
|
34.22
|
8.491
|
43.01
|
17.04
|
17.04
|
17.04
|
P/E ratio
|
-3.84
x
|
46.8
x
|
-0.68
x
|
-0.26
x
|
-1.33
x
|
-0.68
x
|
-0.54
x
|
-0.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
2.43
x
|
-
|
-
|
-
|
-
|
-
|
0.86
x
|
EV / Revenue
|
-
|
2.43
x
|
-
|
-
|
-
|
-
|
-
|
0.86
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,388,599
x
|
-2,952,464
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,878
|
5,334
|
5,340
|
5,340
|
6,993
|
6,993
|
-
|
-
|
Reference price
2 |
56.88
|
18.72
|
6.408
|
1.590
|
6.150
|
2.436
|
2.436
|
2.436
|
Announcement Date
|
3/9/20
|
3/8/21
|
3/1/22
|
3/8/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
41.18
|
-
|
-
|
-
|
-
|
-
|
19.76
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-75.87
|
1.847
|
-45.37
|
-25.23
|
-23.12
|
-25.91
|
-46.38
|
-93.84
|
Operating Margin
|
-
|
4.49%
|
-
|
-
|
-
|
-
|
-
|
-474.99%
|
Earnings before Tax (EBT)
1 |
-74.44
|
1.941
|
-51.71
|
-32.11
|
-30
|
-32.41
|
-54.81
|
-104.2
|
Net income
1 |
-72.18
|
1.941
|
-49.91
|
-32.11
|
-30
|
-32.41
|
-54.81
|
-104.2
|
Net margin
|
-
|
4.71%
|
-
|
-
|
-
|
-
|
-
|
-527.49%
|
EPS
2 |
-14.80
|
0.4000
|
-9.360
|
-6.010
|
-4.610
|
-3.570
|
-4.540
|
-5.610
|
Free Cash Flow
|
-43.43
|
-33.82
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-82.14%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/8/21
|
3/1/22
|
3/8/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-7.518
|
-21.38
|
-7.989
|
-6.965
|
-5.207
|
-5.07
|
-5.349
|
-4.52
|
-6.079
|
-7.172
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-9.205
|
-23.11
|
-9.764
|
-8.718
|
-6.9
|
-6.726
|
-6.97
|
-6.192
|
-7.82
|
-9.022
|
-
|
-
|
-
|
-
|
Net income
|
-9.205
|
-21.31
|
-9.764
|
-8.718
|
-6.9
|
-6.726
|
-6.97
|
-6.192
|
-7.82
|
-9.022
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
1 |
-1.760
|
-4.000
|
-1.840
|
-1.630
|
-1.290
|
-1.260
|
-1.310
|
-1.120
|
-1.030
|
-
|
-1.200
|
-0.7700
|
-0.8100
|
-0.8600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
3/1/22
|
5/4/22
|
8/9/22
|
11/9/22
|
3/8/23
|
5/15/23
|
8/1/23
|
11/7/23
|
2/22/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-43.4
|
-33.8
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/20
|
3/8/21
|
3/1/22
|
3/8/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
2.436
USD Average target price
11
USD Spread / Average Target +351.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -60.38% | 17.04M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|